Arcturus Therapeutics
ARCT
139 hedge funds and large institutions have $694M invested in Arcturus Therapeutics in 2021 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 51 increasing their positions, 37 reducing their positions, and 44 closing their positions.
38% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 37
6.45% more ownership
Funds ownership: 71.49% → 77.94% (+6.4%)
11% less capital invested
Capital invested by funds: $776M → $694M (-$81.8M)
14% less funds holding
Funds holding: 162 → 139 (-23)
22% less call options, than puts
Call options by funds: $6.57M | Put options by funds: $8.41M
52% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 44
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NAMA
Nikko Asset Management Americas
New York
|
+$30.4M |
| 2 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
+$30.4M |
| 3 |
State Street
Boston,
Massachusetts
|
+$12.1M |
| 4 |
Bank Julius Baer & Co
Zurich,
Switzerland
|
+$9.72M |
| 5 |
D.E. Shaw & Co
New York
|
+$7.62M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$15.1M |
| 2 |
O
OrbiMed
New York
|
-$12.1M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$6.45M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$5.92M |
| 5 |
Millennium Management
New York
|
-$4.34M |
ARCT Hedge Fund Activity: Q2 2021 in Review
139 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Arcturus Therapeutics (ARCT) for Q2 2021, worth a combined $694M — down 11% from $776M a quarter earlier.
Sellers outnumbered buyers: 44 funds closed out of ARCT and 21 opened new positions — a net loss of 23 holders — while 37 trimmed existing stakes and 51 added.
The largest buyer was Nikko Asset Management Americas, adding an estimated $30.4M. The largest seller was ARK Investment Management, cutting an estimated $15.1M.
- 139 institutional investors held Arcturus Therapeutics (ARCT) as of Q2 2021, down from 162 in Q1 2021.
- Funds reported $694M of Arcturus Therapeutics stock for Q2 2021, down 11% quarter-over-quarter.
- 21 funds opened new Arcturus Therapeutics positions in Q2 2021 and 44 closed out, a net change of -23 holders.
- The largest Arcturus Therapeutics buyer in Q2 2021 was Nikko Asset Management Americas, an estimated $30.4M added.
- The largest Arcturus Therapeutics seller in Q2 2021 was ARK Investment Management, an estimated $15.1M sold.
Based on aggregated 13F filings for Q2 2021.